The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure

In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher...

Full description

Saved in:

Bibliographic Details
Published in:	Cell metabolism Vol. 30; no. 5; pp. 847 - 849
Main Authors:	Bhatt, Deepak L, Verma, Subodh, Braunwald, Eugene
Format:	Journal Article
Language:	English
Published:	United States 05-11-2019
Subjects:	Benzhydryl Compounds - therapeutic use Comorbidity Diabetes Mellitus, Type 2 - epidemiology Glucosides - therapeutic use Heart Failure - drug therapy Heart Failure - epidemiology Heart Failure - metabolism Heart Failure - prevention & control Humans Sodium-Glucose Transporter 2 - metabolism Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Stroke Volume Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher in a new paradigm in the treatment of heart failure.
ISSN:	1550-4131 1932-7420
DOI:	10.1016/j.cmet.2019.10.008